| Document |
Document Title |
|
WO/2022/017444A1 |
a compound (as represented by formula I) serving as an Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor, as well as a pharmaceutical composition thereof, a preparation method therefor, and a use in treatin...
|
|
WO/2022/020552A1 |
The present invention provides compounds of the structural Formula (I), and pharmaceutically acceptable salts thereof, wherein, are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combin...
|
|
WO/2022/016690A1 |
Provided are luciferase substrates, a preparation method therefor and an application thereof. The luciferase substrates have the advantages of good selectivity, high sensitivity, a low detection line and good biocompatibility, and so on;...
|
|
WO/2022/020342A1 |
Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.
|
|
WO/2022/012593A1 |
A compound represented by general formula (1), a preparation method therefor, and a use of the compound represented by general formula (1), an isomer thereof, a crystal form thereof, a pharmaceutically acceptable salt thereof, a hydrate ...
|
|
WO/2022/015047A1 |
The present invention relates to a novel compound exhibiting excellent light-emitting performance and an organic electroluminescent device comprising same. The compound according to the present invention is used as a material for an orga...
|
|
WO/2022/014721A1 |
The present invention addresses the problem of providing a photoelectric conversion element that has a photoelectric conversion film having superior vapor deposition suitability and exhibits excellent external quantum efficiency with res...
|
|
WO/2022/008912A1 |
Benzodiazepine derivatives of formula (lb) wherein: R1 is H or halo; Y is selected from O, S, SO, SO2 and NR; one or two of V, W and X is or are N or CH and the other one or two is or are CH; R2 is a group selected from C1-C6 alkyl, C1-C...
|
|
WO/2022/007810A1 |
A tricyclic pyrimidinone compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein the compound has a structure as represented by formula (I), is a completely new Lp-PLA2 inhibitor, and can be used for...
|
|
WO/2022/008911A1 |
Benzodiazepine derivatives of formula (Ie) wherein one of R1 and R2 is a benzodiazepinyl-containing group of formula (II) in which R8 is H or halo; the other of R1 and R2 is a group Z selected from H, C3-C6 cycloalkyl, halo, -NHR9, benzy...
|
|
WO/2022/005898A1 |
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed com...
|
|
WO/2022/006543A1 |
The present disclosure features compounds e.g. of formula (I-a) and similar compounds e.g. of formulae (l-g), (l-i), (l-j), (III), (lll-a), (III- b) and (IV) disclosed herein and other related compounds, and pharmaceutical compositions t...
|
|
WO/2022/006129A1 |
This invention is directed to compositions including IRAK4 inhibitors useful for the treatment of dermatological disorders or conditions characterized by inflammation. This invention is also directed to methods for treating the dermatolo...
|
|
WO/2021/263079A1 |
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds for inhibiting three prime repair exonuclease 1 ("TREX1").
|
|
WO/2021/261389A1 |
The present invention provides a photoelectric conversion element, an image pickup element, an optical sensor, and a compound that exhibit excellent external quantum efficiency and responsiveness with respect to light having any waveleng...
|
|
WO/2021/262990A1 |
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclose...
|
|
WO/2021/261447A1 |
The present invention addresses a first problem of providing a photoelectric conversion element having high external quantum efficiency and little response variation. The present invention also addresses a second problem of providing an ...
|
|
WO/2021/262786A1 |
The disclosure relates, in certain aspects, to the discovery of certain compounds that are useful to treat and/or prevent fungal infections in a subject. The disclosure further relates, in certain aspects, to the discovery of certain com...
|
|
WO/2021/261563A1 |
In the production of crops in agriculture, horticulture and the like, the occurrence of damages by pests and the like has been still a major issue, and therefore the development of novel agricultural/horticultural insecticides has been d...
|
|
WO/2021/257977A1 |
Arylsulfonamides of carboxamido-piperidines, -pyrrolidines, and -azetidines, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment o...
|
|
WO/2021/257490A1 |
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression...
|
|
WO/2021/252644A1 |
The disclosure provides compounds of formula II with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provid...
|
|
WO/2021/250102A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds (formula (I)), and their use as MCL-1 inhibitors, useful for treating disease...
|
|
WO/2021/250399A1 |
The invention provides compounds of formula I, wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds ...
|
|
WO/2021/249234A1 |
A compound represented by general formula (I) or stereisomers thereof and pharmaceutically acceptable salts, solvates or prodrugs thereof, a preparation method therefor and a pharmaceutical composition containing the compound. An applica...
|
|
WO/2021/252661A1 |
The disclosure relates to compounds that act as allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, incl...
|
|
WO/2021/250635A1 |
The present disclosure is in the field of pharmaceutical and chemical sciences. The present disclosure generally relates to the synthesis of therapeutic agents, processes for preparing said agents, compositions comprising said therapeuti...
|
|
WO/2021/249492A1 |
Provided are a new methyl-substituted benzobisoxazole compound and the use thereof in the preparation of drugs for treating related diseases. Specifically disclosed is a compound represented by formula (P) or a pharmaceutically acceptabl...
|
|
WO/2021/247634A1 |
Provided herein are compounds of Formula (I''), Formula (I'), Formula (I), Formula (II'), and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labele...
|
|
WO/2021/205631A9 |
The present invention addresses the problem of providing a pharmaceutical having, as an active ingredient, a compound having agonistic activity on STING. As a result of having performed thoroughgoing studies, the inventors discovered, ...
|
|
WO/2021/247732A1 |
The present invention relates to compounds of formula I (I) as well as to the compounds of formula I for use as transmembrane serine protease 2 (TMPRSS2) inhibitors in the treatment of viral infections, such as e.g. corona virus infectio...
|
|
WO/2021/244645A1 |
A novel five-membered heteroaromatic imidazole compound and use thereof in preparing a medicament for treating related diseases. Specifically, disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt ther...
|
|
WO/2021/216665A9 |
The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound heali...
|
|
WO/2021/238908A1 |
The present invention relates to a salt and a crystal form containing a heteroaryl derivative. The present invention specifically relates to a salt and a crystal form comprising a compound of general formula (I), a preparation method, an...
|
|
WO/2021/242955A1 |
The present disclosure relates to thiazolo-pyridine, oxazolo-pyridine, pyrrolo-pyridine, pyrrolo-pyrazine and pyrrolo-pyrimidine compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, me...
|
|
WO/2021/241741A1 |
The present invention provides a photoelectric conversion element having excellent sensitivity, an image sensor, an optical sensor, and a compound. The photoelectric conversion element of the present invention has a conductive film, a ph...
|
|
WO/2021/233227A1 |
Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2021/230512A1 |
Provided is a benzazole derivative that effectively absorbs a high-energy external light source in a UV region so as to minimize damage to organic materials inside an organic electroluminescent device, thereby contributing to a substanti...
|
|
WO/2021/228123A1 |
Provided are a compound for adjusting the activity of an NMDA receptor, and a pharmaceutical composition and the use thereof. In particular, provided are a compound as represented by formula I, or a pharmaceutically acceptable salt or es...
|
|
WO/2021/230511A1 |
Provided is a benzazole derivative which contributes to improving substantial optical efficiency and viewing angle of an organic electroluminescent device. An organic electroluminescent device according to the present invention comprises...
|
|
WO/2021/230035A1 |
(I) (In formula (I), X1 and X2 are, independently from each other, a fluorine atom, a cyano, an alkoxy that may be substituted by D, an amino that may be substituted by D, an acylamino that may be substituted by D, an aryloxy that may be...
|
|
WO/2021/226168A1 |
Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound F that can be used to prepare them where the variable PG is as defined herein. In particular, provided herein are processes for synthesizi...
|
|
WO/2021/224291A1 |
The present invention relates to tricyclic heterocycles. These heterocyclic compounds are useful as TEAD binders and/or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interaction or binding and for the prevention and/or treatment of...
|
|
WO/2021/224501A1 |
The present disclosure provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of a disease involving gram-positive bacteria.
|
|
WO/2021/225833A1 |
Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound Z that can be used to prepare them. In particular, provided herein are processes for synthesizing compound A1, and salts or solvates there...
|
|
WO/2021/226009A1 |
Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound F, or a salt thereof, wherein R1 and OPG2 are described herein. Com...
|
|
WO/2021/225823A1 |
Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound D, wherein OPG and R1 are described herein. Compound D can be usefu...
|
|
WO/2021/222353A1 |
The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to...
|
|
WO/2021/222366A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2021/221032A1 |
The present invention addresses the problem of providing a photoelectric conversion element that exhibits excellent external quantum efficiency and responsiveness with respect to light having any wavelength among a red wavelength range, ...
|
